Foster Stockbroking bullish on SDI

Published 30-JAN-2017 15:08 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Foster Stockbroking has initiated coverage of SDI with a buy recommendation and a 12 month price target of $1.36, a premium of 80% to Friday’s closing price of 75.5 cents.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Founded in 1971, SDI is Australia’s largest dental manufacturer with prominent positions in the areas of amalgam, whitening, aesthetics and equipment.

There has been a significant change in product mix in terms of revenue contribution over the last five years with less reliance on the volatile amalgam business and more of a focus on aesthetics.

While there is a large differential between the company’s recent trading range and the price target, the latter isn’t significantly higher than the group’s 12 month high of $1.16 that was struck just prior to providing a trading update in November that was poorly received.

Earnings skewed to the second half

Management’s main message in providing the trading update was that earnings would be skewed to the second half of the year and that the net profit after tax for the first half would be in a range between $2 million and $2.5 million compared with the previous corresponding period’s $3 million.

Management provided context at the time regarding the skew in earnings, as well as the potential for the foundations for long-term growth to be achieved in March 2017 when the group will have the opportunity to showcase its new products in Germany where it has distribution facilities.

With regard to the first six months, SDI Chief Executive Ms Samantha Cheetham said, “The first six months have traditionally been weaker than the second and I expect the second half will improve and I am confident of meeting our targets”.

Looking to the future, Cheetham said, “Our current focus is on the launch of new products in the second half and these will be showcased at the world’s largest industry trade show to be held in Germany in March 2017, underpinning future growth for the business and highlighting the research and development investments made”.

R&D and IP to drive future earnings and provide barriers to entry

This illustrates the increasing emphasis of research and development, as well as intellectual property in terms of driving the business. Foster Stockbroking sees this as an advantage, and the broker also highlighted that industry regulation is a key barrier to entry.

Taking a five-year view on SDI and eliminating foreign exchange variations, Foster said, “With the increasing momentum in non-amalgam products, we would not be surprised to see growth of more than 10% per annum”.

The broker initiated coverage with a buy recommendation and is forecasting a net profit of $7 million in fiscal 2017, increasing nearly 20% to $8.3 million in fiscal 2018.

This implies fiscal 2018 earnings per share of 7 cents, placing the company on a PE multiple of 10.8 relative to Friday’s closing price.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free